List of Tracleer drug patents
Tracleer is owned by Actelion.
Tracleer contains Bosentan.
Tracleer has a total of 2 drug patents out of which 0 drug patents have expired.
Tracleer was authorised for market use on 05 September, 2017.
Tracleer is available in tablet, for suspension;oral dosage forms.
The generics of Tracleer are possible to be released after 28 December, 2027.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8309126 | ACTELION | Dispersible bosentan tablet |
May, 2026
(3 years from now) | |
| US7959945 | ACTELION | Dispersible bosentan tablet |
Dec, 2027
(4 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Sep 5, 2024 |
Drugs and Companies using BOSENTAN ingredient
Market Authorisation Date: 05 September, 2017
Treatment: NA
Dosage: TABLET, FOR SUSPENSION;ORAL
How can I launch a generic of TRACLEER before it's patent expiration?
More Information on Dosage
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic